Alzamend Neuro Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.60next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly2.7MTarget: Sufficient capital to fund Phase II trials in MDD, PTSD, and Alzheimer's
Stockholders' Equity Quarterly2.2MTarget: >= 2500000 (Nasdaq continued listing requirement)
Accumulated Deficit Quarterly-64.4MTarget: Stabilization post-commercialization
Watch Items
- Nasdaq Stockholders' Equity ComplianceTrigger: Below $2.5 million threshold (reported at $2.18 million as of Jan 31, 2026)Action: Submit and execute a compliance plan to regain Nasdaq Capital Market listing compliance, potentially utilizing the authorized reverse stock split or additional equity financing.
- AL001 Phase II Bipolar Disorder Trial ProgressTrigger: Release of topline data expected in Q3 2026Action: Evaluate pharmacokinetics and brain-structure delivery of lithium compared to standard lithium carbonate in patients.
- Capital Raising for Expanded Phase II TrialsTrigger: Initiation of MDD, PTSD, and Alzheimer's trials in latter half of 2026Action: Secure additional funding or strategic partnerships to support clinical trial expansion.
Research as of 20 Jun 2026